

NOVEL MOUSE MODEL OF ADVANCED VULNERABLE ATHEROSCLEROSIS

Professor Martin Bennett and his team have developed a novel mouse model of advanced atherosclerosis that exhibits the key symptoms of the human disease in a system that offers high levels of experimental control.

- Mice exhibit the key features of advanced vulnerable atherosclerotic plaques including:
 - thin fibrous caps
 - plaque inflammation
 - large necrotic cores
- Model has been validated with Lipitor

For further information please contact:

Dr Andrew Walsh

✉ andrew.walsh@enterprise.cam.ac.uk

☎ +44 (0)1223 760339

Cambridge Enterprise Limited, University of Cambridge
Hauser Forum, 3 Charles Babbage Road, Cambridge CB3 0GT, UK
www.enterprise.cam.ac.uk

Case Ref: Ben-840-03



Background


The death of vascular smooth muscle cells (VSMCs) is a key event in cardiovascular disease. It is a major cause of atherosclerotic plaque rupture leading to heart attack and stroke. There is no easy-to-use animal model of VSMC apoptosis or induced plaque rupture to test drugs that may stabilise plaques. Due to this, development of drugs to inhibit stroke or heart attack has been hampered.

The Technology

Professor Martin Bennett, Murray Clarke and Trevor Littlewood at the University of Cambridge have generated a mouse model in which the human diphtheria toxin receptor (hDTR) is expressed under the control of the VSMC specific promoter SM22 α .

When SM22 α -hDTR mice are treated with diphtheria toxin (DT), VSMC apoptosis is induced, and long term DT administration results in a 50-70% VSMC loss. Crossing SM22 α -hDTR mice with ApoE^{-/-} mice and administering DT gives SM22 α -hDTR/ApoE^{-/-} mice that develop plaques with multiple features of vulnerability.

Figure 1. VSMC apoptosis promotes a vulnerable atherosclerotic plaque phenotype



Studies have revealed that VSMC apoptosis induces plaque inflammation within SM22 α -hDTR/ApoE^{-/-} mice. These mice display intense localised macrophage-rich inflammatory infiltrates, with extensive cellular debris.

Expression of the pro-inflammatory cytokine MCP-1 is evident in the fibrous cap. Validation of the model has also been undertaken using Atorvastatin (Lipitor) (see Fig. 2 below).

The ability of cardiovascular compounds to stabilise atherosclerotic plaques may therefore be measured by administering compounds of interest with DT to SM22 α -hDTR/ApoE^{-/-} mice and subsequent examination of the features of plaque vulnerability. This model therefore has great potential as a tool to aid cardiovascular drug development.

Reference

Clarke, M *et al* Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. *Nature Medicine* 2006 August 6.

Commercialisation

We are seeking to establish licensing relationships for the commercialisation of this technology in research and development including initial evaluation deals where appropriate.

Figure 2. Atorvastatin prevents inflammation following DT-induced VSMC apoptosis

